BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230110
DTEND;VALUE=DATE:20230113
DTSTAMP:20260516T045858
CREATED:20221007T084856Z
LAST-MODIFIED:20221007T084856Z
UID:35427-1673308800-1673567999@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes and Injectable Drug Devices Europe
DESCRIPTION:SAE Media Group’s 15th Annual Conference \nPre-Filled Syringes and Injectable Drug Devices Europe \nJanuary 10 – 12 2023 | London\, UK \nhttp://www.pre-filled-syringes.com/pharmajournalist \n————————————————————————- \nThe pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to increase patient centricity\, aid self-administration and deliver biologics that have large-volumes and novel formulations. This year’s conference will explore the exciting advances in the combination product drug delivery space and a future outlook exploring how pharma\, device developers and regulators can work together to encourage innovation. \n \nSAE Media Group’s 15th Annual Pre-Filled Syringes and Injectable Drug Devices Conference will be bigger than ever\, with a pre-conference focus day exploring the advances in PFS design for enhanced drug delivery proceeded by a two-day main conference comprising of morning keynote plenaries and parallel afternoon topic streams as detailed below: \n\nNovel Drug Products and Large Volume Delivery\nSustainability for Injectable Delivery Devices\nPrimary Packaging Development\nConnected Drug Delivery Devices\n\nTopics of discussion will include the latest updates in the combination product regulatory framework\, insights into the evolving digital health landscape for connected delivery devices\, considerations for the development of primary packaging\, utilising platform technology\, the delivery of novel drug formulations and large volume drug products\, patient centric approaches to device design as well as sustainable approaches for device development. \nThis event will not only bring you key insights you need to expand and enhance your injectable device portfolio but will also give you the opportunity to network with key players throughout the industry. \nBenefits of Attending: \n\nEngage with industry representatives on the latest trends within the pre-filled syringe and injectable device market\nHear about new technological advances in the delivery of large volume drugs\nExplore updates to drug device combination product design approaches considering patient preference at the forefront with case studies from big pharma representatives\nUnderstand the latest regulatory requirements from regulatory experts surrounding medical devices and digital health\nDelve into the considerations for material components for the development of primary packaging\nGain insight into how big pharma are incorporating sustainable approaches into drug device design\n\nWho should attend: \nAdvanz Pharma; AstraZeneca; Balda Medical GmbH & Co. KG; Bayer AG; Bayer Pharma; BD Medical; BD Medical – Pharmaceutical Systems; Becton Dickinson (BD); Boehringer Ingelheim; Boehringer Ingelheim GmbH & Co. KG; Boehringer Ingelheim Pharma GmbH & CO KG; Boehringer Ingelheim Pharma Gmbh & Co. Kg; BSI; BSI Group; Chiesi Ltd; Crux Product Design Ltd; DCA Design International; Device Development; Dr.Reddys; GlaxoSmithKline; GSK; Hoffmann-La Roche; Horizon Therapeutics GmbH; Ichnos Sciences; Janssen Pharmaceutical Companies; Johnson & Johnson; Johnson & Johnson (Janssen Pharmaceutical); Medincell; Merck Group; Midas Pharma Gmbh; Nemera; Novartis; Novo Nordisk; Novo Nordisk A/S; Owen Mumford; Pfizer; Pfizer UK; PharmaEssentia; Prescient Healthcare Group; RAUMEDIC AG; Sanofi; SCHOTT AG; SPM MEDICARE PVT LTD\, INDIA; Sustainable Healthcare Coalition; Takeda; Teva; Teva Pharmaceuticals; Teva Pharmaceuticals Industries Ltd.; Teva\, Combination Products; TUV Italia SRL; TUV SUD Japan Ltd.; TUV SUD Product Service GmbH; University of Liverpool; University of Southern Denmark; Zeon Europe GmbH; Zeon Specialty Materials ; \nSAE Media Group offer direct access to key decision makers through tailored sponsorship and exhibitor packages. \nFor details\, please contact Daniele Moreschi on: +44 (0)20 7827 6050 or dmoreschi@smi-online.co.uk \nFor all delegate enquiries\, contact Jamie Wilkinson on: +44 (0) 20 7827 6136 or jwilkinson@smi-online.co.uk \nAbout SAE Media Group Conferences: \nSAE Media Group Conferences connects global communities with focused networking conferences. We provide our customers with solutions through industry knowledge and collaboration that enables our attendees to return to their organisations better equipped to overcome their key business challenges. Our key events focus on Defence and Aerospace\, Pharmaceutical and Medical.  Each year we bring together over 5\,000 senior business professionals at our conferences. http://www.smgconferences.com \nSAE Media Group (SMG)\, a subsidiary of SAE International\, reports the latest technology breakthroughs and design innovations to a global audience of nearly 1\,000\,000 engineers\, researchers\, and business managers. SMG provides critical information these professionals need to develop new and improved products and services.
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-and-injectable-drug-devices-europe/
LOCATION:London\, UK
ORGANIZER;CN="SAE Media Group":MAILTO:RJones@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230116
DTEND;VALUE=DATE:20230118
DTSTAMP:20260516T045858
CREATED:20220926T093554Z
LAST-MODIFIED:20220926T100546Z
UID:35289-1673827200-1673999999@www.pharmajournalist.com
SUMMARY:11th Annual Pharmaceutical Microbiology Conference
DESCRIPTION:11th Annual Pharmaceutical Microbiology Conference  \n16 – 17 January 2023 \nLondon\, UK\nhttp://www.pharma-microbiology.com/PJwl \n Sponsored by: Microgenetics  \nCo-chairs Di Morris\, Clinical Auditor\, AstraZeneca and Nigel Cryer\, Deputy Director Global Audit\, Sanofi  \nHarnessing Alternative Rapid Microbial Methods for a Successful Contamination Control Strategy  \n \nWe are delighted to announce SAE’s 11th Annual Pharmaceutical Microbiology Europe Conference taking place in London\, UK on the 16-17 January 2023. \nMicrobiology remains an essential tool for the detection of microorganisms present in biopharmaceutical and pharmaceutical batches. This conference will explore the most pressing topics in this thriving field\, from the movement toward process automation and increased regulatory stringency\, to the latest technologies in rapid microbiological testing methods and data integrity. \nEvent Hashtag: #MicrobiologyEurope \nKey Highlights for 2023 Conference: \n\nOptimise your contamination control strategy and review the initial impact of Annex 1\nLearn how to utilise the latest microbiological methods to modernise your contamination control strategy\nMaximise the data output from your environmental and microbial monitoring with proven strategies and technologies\nIncrease the diversity of your testing methodologies through industry case studies including the recombinant factor C assay and Monocyte Activation Test\n\nWho Should Attend? \nHeads of Microbiology\, Heads of Aseptic Processing\, Global Quality Directors\, Heads of GMP Compliance\, Quality & Compliance Heads\, Microbiology Senior Specialists\, Directors of Quality Control Biology\, Quality Control Managers\, Quality Assurance Managers\, Lean Managers\, Operations Managers\, Heads of Site Compliance\, Heads of Sterile Technology\, Global Microbiology Analytical Experts\, Cleanroom Managers\, Regulatory Affairs Managers\, Production Managers\, Quality Systems Managers \nDownload the brochure at: http://www.pharma-microbiology.com/PJwl
URL:https://www.pharmajournalist.com/event/11th-annual-pharmaceutical-microbiology-conference/
LOCATION:London\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230117
DTEND;VALUE=DATE:20230120
DTSTAMP:20260516T045858
CREATED:20221021T090337Z
LAST-MODIFIED:20221021T090337Z
UID:35537-1673913600-1674172799@www.pharmajournalist.com
SUMMARY:Spatial Biology for Immuno-Oncology Summit
DESCRIPTION:The inaugural Spatial Biology for Immuno-Oncology Summit runs at a crucial moment in time. Spurred on by technological advancement and successful case studies\, spatial technologies are set to become increasingly mainstream and accessible. If you’re not already\, now is the time to harness spatial technologies to power your immunotherapy research\, improve your clinical trials\, enhance your biomarker discovery\, and streamline your therapeutic development. \nUniting researchers\, technology providers\, and drug developers\, next January join your peers to hear the latest best-practice case studies on operationalizing technology\, integrating spatial into the clinic\, and developing a robust data analysis pipeline. This meeting will provide an unrivaled opportunity to solve your current spatial challenges to improve your ability to treat disease and identify drug targets in immuno-oncology. \nAcross 3 jam-packed days of content\, led by 20+ immuno-oncology leaders\, the Spatial Biology for Immuno-Oncology Summit is your only chance to discover how technologies that put omics and single-cell information in spatial context can improve your ability to treat disease and identify drug targets in immuno-oncology. \nJoin over 100 key industry stakeholders as they gather and leave no stone unturned to advance the application of this revolutionary technology. \nTo know more visit: https://bit.ly/3yYeUhw
URL:https://www.pharmajournalist.com/event/spatial-biology-for-immuno-oncology-summit/
LOCATION:The Westgate Hotel\, 1055 2nd Ave\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230123
DTEND;VALUE=DATE:20230125
DTSTAMP:20260516T045858
CREATED:20221007T091733Z
LAST-MODIFIED:20221007T091733Z
UID:35438-1674432000-1674604799@www.pharmajournalist.com
SUMMARY:Transdermal and Microneedle Drug Delivery
DESCRIPTION:SAE Media Group’s 2nd Annual Conference \nTransdermal and Microneedle Drug Delivery \nJanuary 23 – 24\, 2023 | London\, UK \nwww.transdermal-microneedle-delivery.co.uk/pharmajournalistel \n————————————————————————- \nSAE Media Group is proud to present the 2nd annual Transdermal and Microneedle Drug Delivery Conference\, taking place on the 23rd to 24th January 2023. \n \nThe 2023 Transdermal and Microneedle Drug Delivery Conference will explore real world applications of microneedles in drug delivery and strategies for advanced and user-centric device design. Regulation of transdermal delivery systems will be another key theme addressed\, in combination with clinical trial optimization. Engage in the latest innovations in device design\, development and formulation\, with case studies from expert key opinion leaders of this rapidly accelerating space. Other key areas will be microneedle vaccines and transdermal patches for management of chronic disease. \nThe two-day agenda offers you peer-to-peer networking with CEO’s\, Senior Vice presidents\, Directors\, Heads of Product Development and many more. \nBENEFITS OF ATTENDING: \n\nEngage with senior industry opinion leaders presenting their experiences and case studies in innovative device design and advanced drug product formulation\nGain insights from notified body and competent authority representatives addressing key regulatory requirements\nUnderstand how to optimize your lifecycle management strategy for a commercially successful device\nExplore and benchmark against industry advances in device design through case studies and real-world examples\n\nWHO SHOULD ATTEND: \n\nDrug-Delivery Device Developers\nMicroneedle Device Developers\nTransdermal Delivery Developers\nMicroarray Patch Developers\nMedical Device Engineers\nPrimary Packaging Material Designers\nSecondary Packagers\nSmart Device Developers\nTraining Device Developers\nDevice-Safety Solution Providers\nDrug Developers\nTransdermal Drug Product Developers\n\nEARLY-BIRD RATES:  \n\nBOOK BY 30TH SEPTEMBER AND SAVE £400\n\nRegistrations can be made on the event website at: www.transdermal-microneedle-delivery.co.uk/ \nTargeted Keywords \nTransdermal and Microneedle Drug Delivery\, transdermal\, drug development\, regulatory guidelines\, pharmaceutical industry\, drug delivery\, therapeutic sectors\, vaccines\, Parenteral administration\, combination products\, primary packaging\, sterile injectables\, connectivity\, human factors\, autoinjectors
URL:https://www.pharmajournalist.com/event/transdermal-and-microneedle-drug-delivery/
LOCATION:London\, UK
ORGANIZER;CN="SAE Media Group":MAILTO:RJones@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230124
DTEND;VALUE=DATE:20230127
DTSTAMP:20260516T045858
CREATED:20220826T121137Z
LAST-MODIFIED:20220831T191624Z
UID:35017-1674518400-1674777599@www.pharmajournalist.com
SUMMARY:2nd Annual mRNA-Based Therapeutics Summit Europe
DESCRIPTION:The 2nd Annual mRNA-Based Therapeutics Summit Europe is the only end-to-end mRNA-dedicated meeting in Europe and the largest gathering for mRNA professionals outside of the United States. \nBuilt with biopharmaceutical industry insights\, this meeting will unite KOLs from Europe and the rest of the world to delve into the challenges associated with successfully designing and developing the next-generation of mRNA-based vaccines & therapeutics with improved specificity\, delivery & efficacy for immuno-oncology\, infectious diseases and beyond. \nHear from 35+ pioneering large pharma\, biotech\, and academic experts who are shaping the landscape of mRNA-based therapeutics and discover how they are addressing the major challenges facing the industry. \nWith more companies investing in their tools and technologies to innovate processes and technologies to address key challenges such as sequence optimization\, cell-specific payload expression\, and durability\, there has never been a more pivotal time to join European biopharma experts and discuss the following topics. \n-Emerging cell-enhancing or protein replacement therapies based on mRNA \n-Optimization of analytical and quality control protocols \n-Durability\, accessibility and immunogenicity challenges of mRNA therapeutics and vaccines \n-Enhancement of formulation\, process development and manufacturing processes \n-Need for clear regulatory path to support the technology whilst enabling speed to market \nTo learn more\, download your copy of the full event guide including all speakers and their session details: https://ter.li/tholw0
URL:https://www.pharmajournalist.com/event/2nd-annual-mrna-based-therapeutics-summit-europe/
LOCATION:TBC – Berlin\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:mailto:info@hansonwade.com?subject=2nd Annual mRNA-Based Therapeutics Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230124
DTEND;VALUE=DATE:20230127
DTSTAMP:20260516T045858
CREATED:20221011T104423Z
LAST-MODIFIED:20221208T115612Z
UID:35446-1674518400-1674777599@www.pharmajournalist.com
SUMMARY:DDR Inhibitors Summit 2023
DESCRIPTION:The 6th DDR Inhibitors Summit is taking place in-person for the first time in 3 years in Boston\, MA this January 24 – 26\, 2023. \nThe DNA damage response inhibitor space only continues to grow\, with progress being accelerated by a shift in focus onto next-generation targets like PolQ and WRN\, moving forward from monotherapies through combining targets and exploiting sensitivity caused by DDRis to enhance other therapies like radiotherapy. \nThe scope of this year’s meeting is to bring together leading minds in DDRi drug development to exploring these strategies and aim to address issues related to emerging DDR inhibitor resistance and maximizing efficacy\, as well as addressing the biggest challenge in the space right now\, toxicity. \nThe 3-day meeting will consist of a comprehensive overview of the DDR space\, with over 30+ world class speakers sharing insights preclinical updates\, progress in the clinic\, solutions to overcoming toxicity and improving patient selection. \nDon’t miss out on hearing from the best in the field on how to overcome toxicity and resistance during drug design as well as in the clinic\, to maximize efficacy and propel your DDR inhibitors to success. \nTo know more visit: https://ter.li/40qr50
URL:https://www.pharmajournalist.com/event/ddr-inhibitors-summit-2023/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230124
DTEND;VALUE=DATE:20230127
DTSTAMP:20260516T045858
CREATED:20221110T115619Z
LAST-MODIFIED:20221110T115619Z
UID:35763-1674518400-1674777599@www.pharmajournalist.com
SUMMARY:2nd HFpEF & HCM Drug Discovery & Development Summit
DESCRIPTION:The 2nd HFpEF & HCM Drug Discovery & Development Summit is the definitive industry forum dedicated to propelling drug discovery and development across emerging therapeutics including cell and gene therapies and the implementation of precision medicine. \n \nShake hands with industry pioneers prioritizing the development of therapeutic treatments to complement the new standard of care with SGLT2 inhibitors and understand how you can leverage advances in biomarkers for early detection of drug efficacy and clinical trial updates to inform your strategic decisions. \nJoin 80+ biopharma experts in research\, cardiovascular\, rare disease and precision medicine as they analyze the HFpEF patient population and translational drug development pathway to achieve new commercially viable and clinically accepted therapeutics. \nTo know more visit: https://bit.ly/3EjK5H3
URL:https://www.pharmajournalist.com/event/2nd-hfpef-hcm-drug-discovery-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230130
DTEND;VALUE=DATE:20230202
DTSTAMP:20260516T045858
CREATED:20221121T083953Z
LAST-MODIFIED:20221121T083953Z
UID:35900-1675036800-1675295999@www.pharmajournalist.com
SUMMARY:3rd TGF-β for Immuno-Oncology Drug Development Summit
DESCRIPTION:Exploit Understanding of TGF-β Biology\, Harness Clinically Validated Biomarkers & Advance Safe & Efficacious Clinical Programs for Maximal Therapeutics Benefit in Immuno-Oncology. \nIn the past year alone\, the field has learnt valuable lessons from the clinical trials and from the wider TGF-β field that will equip the immuno-oncology field with the knowledge needed to supercharge future TGF-β monotherapy or combinational therapeutics for precision medicine. \nFrom uncovering the effects and production of TGF-β in immune\, tumor and stromal cells to exploring predictive and pharmacodynamic TGF-β biomarkers for patient identification and assessing the clinical challenges that led to recent clinical failures\, the 3rd TGF-β for Immuno-Oncology Drug Development Summit is your one-stop-shop dedicated to harnessing you with the knowledge to unlock the potential of successfully targeting TGF-β. \nTailored with 18+ senior leaders\, the 2023 meeting will be taking place in-person for the first time – don’t miss your chance to be in the room for your comprehensive guide on TGF-β in immuno-oncology! \nWhether you are new to this field or a seasoned expert\, this meeting will provide you with the must-know takeaways from the basic biology to biomarkers to clinical trial design to overcome the clinical setbacks and produce a blockbuster TGF-β therapeutic. \nTo know more visit: https://ter.li/cjnpgy
URL:https://www.pharmajournalist.com/event/3rd-tgf-%ce%b2-for-immuno-oncology-drug-development-summit/
LOCATION:Marines Memorial Club and Hotel\, 609 Sutter St\, San Francisco\, CA\, 94102\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR